Piotr L. Rutkowski

Piotr L. Rutkowski

Cracow Branch
Krakow, MA, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 552 publications

COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma.

COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 12, 2026

Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial.

Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 11, 2026

Optimising Clinical Outcomes Following R1 Resection in Soft Tissue Sarcoma: An Evidence-Based Approach.

Optimising Clinical Outcomes Following R1 Resection in Soft Tissue Sarcoma: An Evidence-Based Approach.

Journal: Current treatment options in oncology

Published: July 24, 2026

Pathologic assessment of response to neoadjuvant therapy in melanoma - recommendations for the evaluation of post-resection specimens.

Pathologic assessment of response to neoadjuvant therapy in melanoma - recommendations for the evaluation of post-resection specimens.

Journal: Polish journal of pathology : official journal of the Polish Society of Pathologists

Published: July 16, 2026

Rare Molecular Variants of Gastrointestinal Stromal Tumors (GISTs): Clinical Implications and Overview of Current Evidence.

Rare Molecular Variants of Gastrointestinal Stromal Tumors (GISTs): Clinical Implications and Overview of Current Evidence.

Journal: Targeted oncology

Published: June 23, 2026

Accelerating real-world data collection using large language models in rare neoplasms: a bone sarcoma example.

Accelerating real-world data collection using large language models in rare neoplasms: a bone sarcoma example.

Journal: ESMO real world data and digital oncology

Published: April 23, 2026

primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma.

primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 16, 2026

Desmoid Tumors-Biology-Driven Management and Treatment Selection.

Desmoid Tumors-Biology-Driven Management and Treatment Selection.

Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Published: April 13, 2026

Circulating thymidine kinase activity predicts survival and optimal treatment sequencing in BRAF-mutated metastatic melanoma in the SECOMBIT trial.

Circulating thymidine kinase activity predicts survival and optimal treatment sequencing in BRAF-mutated metastatic melanoma in the SECOMBIT trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: April 13, 2026

Detection of Gene Fusions in Soft Tissue Sarcoma Using Next-Generation Sequencing.

Detection of Gene Fusions in Soft Tissue Sarcoma Using Next-Generation Sequencing.

Journal: Genes

Published: March 31, 2026

A phase I study evaluating subcutaneous administration of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced solid malignancies.

A phase I study evaluating subcutaneous administration of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced solid malignancies.

Journal: Cancer immunology, immunotherapy : CII

Published: March 02, 2026

Five-year survival with tebentafusp in metastatic uveal melanoma.

Five-year survival with tebentafusp in metastatic uveal melanoma.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: March 02, 2026

Showing 1-12 of 552

Last Updated: 09/26/2026